Acelyrin Inc
Total Consideration
$238.1M
Share price: $4.78
Purchase-Price Allocation
Intangibles
$51.0M
Assets Acquired
$460.1M
Liabilities Assumed
$34.1M
Deferred Tax Liability
$10.7M
Alumis Inc. — Key Metrics
1 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$-3
Book Value Per Share
$4
Free Cash Flow Per Share
$-4
Cash Per Share
$1
Revenue Per Share
$0
OCF Per Share
$-4
Return on Equity
-86.7%
Return on Assets
-64.6%
Return on Invested Capital
-127.7%
Current Ratio
4.34
Quick Ratio
4.34
Asset Turnover
0.06
R&D / Revenue
1605.0%
SBC / Revenue
181.0%
Capex / Revenue
2.7%
Working Capital
$245M
Net Current Asset Value
$208M
Invested Capital
$301M
OCF / Net Income
1.52
FCF / Net Income
1.52
Accruals Ratio (Sloan)
30.6%
Net Debt
$-309M
Net Debt / EBITDA
0.69
Capex Coverage
-565.89
Tangible Common Equity
$301M
TCE / Total Assets
73.1%
NOPAT
$-359M
Cash ROIC
-131.9%
WC / Revenue
1018.4%
Capex / D&A
0.19
Reinvestment Rate
0.6%
Total Payout Ratio
-0.0%
Stock Price (FY-end)
$10
Market Cap
$830M
P/S Ratio
34.51
P/B Ratio
2.75
P/TB Ratio
2.75
Enterprise Value
$521M
EV / Sales
21.68
FCF Yield
-44.6%
Shareholder Yield
-5.2%
Buyback Yield
0.0%
R&D Yield
46.5%
Capex Yield
0.1%
Shares Variation (YoY)
200.0%
Beta (5Y)
0.71
Cost of Equity
8.1%
52W High
$12
52W Low
$3
Trailing Return 1Y
21.1%
F-Score (Piotroski)
1.00
Z-Score (Altman)
-1.43
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
EPS — Consensus vs Actual
Revenue — Consensus vs Actual
Stock Price on Earnings Dates
Alumis Inc. — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
| Reconciliation Line | FY2024 | FY2025 |
|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% |
| State & Local Income Taxes | — | — |
| Foreign Rate Differential | — | — |
| Other Adjustments | — | — |
| R&D Tax Credits | — | 4.40% |
| SBC (Nondeductible) | — | -1.90% |
| Valuation Allowance Change | — | -25.80% |
| Effective Tax Rate | — | 3.40% |
Cash vs Accrual
| Item | FY2024 | FY2025 |
|---|---|---|
| Income Tax Expense (Accrual) | — | −$8.6M |
| Income Taxes Paid (Cash) | — | — |
Alumis Inc. — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.